In this article, Tischler and Favier explore some of the most fundamental aspects of cancer biology, in the form of the experimental model. The focus here is on phaeochromocytoma and paraganglioma, topics where we do not have the necessary basic understanding of pathobiology in order to progress with suitable preclinical testing.

Due to the seemingly rare nature of both conditions, we lack appropriate models to test potential drug targets. This paper discusses the challenges and most recent advances in the production of test models, with a particular focus on in vitro studies and the necessary considerations as we move forward.

Read the full article in Endocrine-Related Cancer 30 e220405